title: Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes.
authors.forename: Pelle L
authors.initials: PL
authors.lastname: Ishøy
authors.forename: Filip K
authors.initials: FK
authors.lastname: Knop
authors.forename: Tina
authors.initials: T
authors.lastname: Vilsbøll
authors.forename: Birte Y
authors.initials: BY
authors.lastname: Glenthøj
authors.forename: Bjørn H
authors.initials: BH
authors.lastname: Ebdrup
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects / Q000627:therapeutic use; D003024:Clozapine / Q000009:adverse effects / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D005260:Female; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000067757:Glucagon-Like Peptide-1 Receptor; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D000069450:Liraglutide; D008875:Middle Aged; D009765:Obesity / Q000139:chemically induced* / Q000150:complications; D018027:Receptors, Glucagon / Q000819:agonists*; D012559:Schizophrenia / Q000150:complications* / Q000188:drug therapy; D015431:Weight Loss / Q000187:drug effects*
chemical_list: D014150:Antipsychotic Agents; D003024:Clozapine; D052216:Glucagon-Like Peptide 1; D000067757:Glucagon-Like Peptide-1 Receptor; D006442:Glycated Hemoglobin; D000069450:Liraglutide; D018027:Receptors, Glucagon; C000593833:GLP1R protein, human; C517652:hemoglobin A1c protein, human